Akari targets Q1 2027 start for Phase 1 trial of AKTX-101 ADC
PUBT · 04/20 12:39
Share
Listen to the news
- Akari Therapeutics reported positive preclinical results for lead TROP2 antibody-drug conjugate AKTX-101, with data already presented at AACR Annual Meeting 2026.
- Studies showed AKTX-101 delivered stronger cancer cell-killing activity than leading TROP2 ADCs that use topoisomerase I inhibitor payloads, including in models linked to drug resistance.
- Management outlined plans to move AKTX-101 into human testing, targeting an IND submission in Q4 2026.
- Akari expects Phase 1 initiation in Q1 2027, positioning AKTX-101 as a differentiated entrant in TROP2 ADC market projected to reach about USD 12 billion by 2033.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved